Merck & Co eyes growing RSV market with strong clesrovimab data
Merck & Co (NYSE: MRK) has announced encouraging data from a Phase IIb/III clinical trial for clesrovimab, its investigational antibody designed to prevent respiratory syncytial virus (RSV) in infants.
The data, revealed at IDWeek 2024 in Los Angeles, positions clesrovimab as a potential rival to the RSV market leader, Sanofi (Euronext: SAN) and AstraZeneca's (LSE: AZN) Beyfortus (nirsevimab).
The trial tests a single dose of clesrovimab, administered to healthy preterm and full-term infants. The study met all primary endpoints, with RSV-associated lower respiratory infections reduced by 60.4% compared to placebo and RSV-related hospitalizations cut by 84.2%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze